| 38th week of 2022 patent applcation highlights part 26 |
| Patent application number | Title | Published |
|---|
| 20220298192 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Disclosed is a compound including a ligand L | 2022-09-22 |
| 20220298193 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound of Formula I, | 2022-09-22 |
| 20220298194 | PROCESSED LIGNIN AND PROCESS TO PREPARE SUCH - Processed lignin comprising the elements carbon (C), hydrogen (H) and oxygen (O) in the following amounts (upon performing an elemental analysis):
| 2022-09-22 |
| 20220298195 | CLASS OF SUCROSE ESTERS AND A METHOD FOR THEIR PREPARATION - The present invention relates to a new class of sucrose esters and a method for their preparation. | 2022-09-22 |
| 20220298196 | NOVEL COMPOUND DERIVED FROM WATERMELON, AND COMPOSITION USING SAME - Provided is a novel compound that is contained in a young watermelon fruit and has an antioxidative effect. | 2022-09-22 |
| 20220298197 | NOVEL COMPOUNDS - Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment diseases such as urinary tract infection. | 2022-09-22 |
| 20220298198 | NUCLEOTIDE PRODRUG COMPOUNDS - Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection. | 2022-09-22 |
| 20220298199 | CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS - Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer. | 2022-09-22 |
| 20220298200 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION - Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure. | 2022-09-22 |
| 20220298201 | FLUORINATED NUCLEOTIDES AND USES THEREOF - Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof in the sequencing a nucleic acid. | 2022-09-22 |
| 20220298202 | METHODS OF MAKING CHOLIC ACID DERIVATIVES AND STARTING MATERIALS THEREFOR - Methods of making cholic acid derivatives, particularly ursodeoxycholic acid, tauroursodeoxycholic acid, 7-ketolithocholic acid, obeticholic acid, their carboxylate salts and carboxylate esters, and starting materials and intermediates therefor. | 2022-09-22 |
| 20220298203 | THERAPEUTIC AGENTS AND METHODS - The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease. | 2022-09-22 |
| 20220298204 | SYNTHESIS OF A-AMANITIN AND ITS DERIVATIVES - The present invention relates to the chemical synthesis of α-amanitin and its derivatives. The present invention also relates to intermediate products of the α-amanitin synthesis. | 2022-09-22 |
| 20220298205 | METHODS FOR PROTEIN PURIFICATION - The present invention relates to methods of protein purification, in particular using ion exchange chromatography. Modified proteins and peptide tags suitable for use in purification by ion exchange chromatography are provided, as are related methods. | 2022-09-22 |
| 20220298206 | An improved process for the preparation of Etelcalcetide Hydrochloride - The present invention relates to an improved process for the preparation of Etelcalcetide hydrochloride of Formula (I): The present invention also provides a process for preparing Etelcalcetide acetate of Formula (VI), which is an intermediate of Etelcalcetide hydrochloride: Formula (VI) | 2022-09-22 |
| 20220298207 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER - A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer. | 2022-09-22 |
| 20220298208 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LISTERIA VIRULENCE - There are provided herein compounds of Formula I, compositions comprising the compounds, and methods for using the compounds. The methods include methods for modulating quorum sensing by | 2022-09-22 |
| 20220298209 | POLYPEPTIDE AND APPLICATION THEREOF - The present disclosure provides a polypeptide and application thereof. The polypeptide comprises a peptide fragment composed of 16-23 consecutive amino acids in an amino acid sequence represented by SEQ ID NO: 1; or the polypeptide comprises a polypeptide fragment which consists of 16-23 consecutive amino acids of the amino acid sequence of SEQ ID NO: 1 in the opposite direction of the peptide sequence (reverse peptide). The polypeptide can be used to mitigate metabolic syndrome, achieve weight loss, prevent and treat nonalcoholic fatty liver diseases and cardiovascular diseases. | 2022-09-22 |
| 20220298210 | ARTIFICIAL ALPHAVIRUS-DERIVED RNA REPLICON EXPRESSION SYSTEMS - Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided. | 2022-09-22 |
| 20220298211 | PLANT-PRODUCED mABs AGAINST CHIKUNGUNYA VIRUS WITH ENHANCED EFFECTOR FUNCTION AND EFFICACY - Disclosed are monoclonal antibodies against Chikungunya virus having enhanced effector function and efficacy, methods of producing them, and methods of treatment of Chikungunya viral infection using the antibodies. | 2022-09-22 |
| 20220298212 | RECOMBINANT 4-1BB BINDING PROTEINS AND THEIR USE - The present disclosure relates to recombinant binding proteins comprising a designed ankyrin repeat domain with binding specificity for 4-1 BB (CD 137). In addition, the disclosure relates to nucleic acids encoding such binding proteins, pharmaceutical compositions comprising such binding proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for activating 4-1 BB in cells expressing 4-1 BB, e.g., tumor-localized T-lymphocytes, and for treating or diagnosing diseases, such as cancer, in a mammal, including a human. | 2022-09-22 |
| 20220298213 | IN VIVO ENGINEERED CEREBLON PROTEIN - Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO: 1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3. | 2022-09-22 |
| 20220298214 | Highly effective blood-glucose-lowering protein drug - This invention provides a protein that is highly effective in lowering blood glucose. Experimental results have shown that the protein can be used to prepare a drug for treating diabetes. | 2022-09-22 |
| 20220298215 | Multi-receptor (GLP-1 receptor, GIP receptor, and Gcg receptor) agonist protein - This invention provides a novel protein. Experimental results have shown that the protein has agonist activity at three receptors, namely the glucagon-like peptide 1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (Gcg) receptor, and has both blood glucose lowering and body weight reducing functions. | 2022-09-22 |
| 20220298216 | GHRELIN O-ACYLTRANSFERASE (GOAT) IMAGING AGENTS - Imaging agents that can bind to ghrelin O-acyltransferase (GOAT) without binding to the ghrelin receptor (GHS-R1a). The imaging agents comprise a base structure for selective binding to GOAT that is coupled via an amino acid linker to a chemical group to enable imaging such as a fluorescent label, radioactive tracer, or metal chelator. For example, the imaging agent may comprise a ghrelin substrate mimetic inhibitor incorporating an unmodified 2,3-diaminopropanoic acid (Dap) group at the site analogous to serine 3. These agents enable specific detection and imaging of GOAT versus the GHS-R1a receptor in a variety of biological contexts. | 2022-09-22 |
| 20220298217 | MODULATORS OF PARATHYROID HORMONE RECEPTOR (PTHR1) - The invention provides, inter alia, synthetic parathyroid hormones (sPTHs) that can modulate the activity of parathyroid hormone receptor, such as parathyroid hormone receptor 1 (PTHR1). The invention also provides methods of modulating PTHR activity using these sPTHs, e.g., in a cell, such as a cell in an organism. | 2022-09-22 |
| 20220298218 | Modified GIP Peptide Analogues - Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues which are antagonists of the GIP receptor. These GIP peptide analogues are modified by comprising one or more individual amino acid substitutions and are fatty acid conjugated with/without a linker, so to have improved antagonistic activity and improved pharmacokinetic profile. | 2022-09-22 |
| 20220298219 | CYCLIC PEPTIDE ANALOGS OF MELANOCORTIN AND AMANITIN AND METHODS OF MAKING SUCH - The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein. | 2022-09-22 |
| 20220298220 | Neuropilin-1 Specific Binding Peptide, Fusion Protein Fused with Same, and Use Thereof - A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration. | 2022-09-22 |
| 20220298221 | CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) THAT BINDS AUTOANTIBODIES TARGETING THE CENTRAL NERVOUS SYSTEM IN NEUROLOGICAL AUTOIMMUNE DISEASE - A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis. | 2022-09-22 |
| 20220298222 | COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS - Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). | 2022-09-22 |
| 20220298223 | B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS - Provided herein are immuno-responsive cells expressing a B cell targeting pCAR comprising a 2nd generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immuno-responsive cells and methods of directing T cell mediated immune response using the immuno-responsive cells. | 2022-09-22 |
| 20220298224 | DECOY CYTOKINE RECEPTOR - An IL-11 binding receptor capable of binding to IL-11 and inhibiting IL-11 mediated signalling is disclosed. Also disclosed are compositions comprising the IL-11 binding receptor and methods using the IL-11 binding receptor. | 2022-09-22 |
| 20220298225 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH COLLAGEN BINDING DRUG CARRIERS - This disclosure relates to tumor-targeted drug carriers that lead to improved anti-tumor efficacy by efficient delivery of a cytotoxic agent to the tumor microenvironment. Aspects of the disclosure relate to a polypeptide comprising an albumin or IgG Fc domain polypeptide operatively linked to a collagen binding domain. Further aspects relate to a composition comprising a polypeptide, nucleic acid, or cell of the disclosure. | 2022-09-22 |
| 20220298226 | METHACRYLATED COLLAGEN - The present invention provides a novel collagen methacrylamide, methods by which the collagen methacrylamide may be manufactured and uses for said novel collagen methacrylamide, such as 3D-printing, in the treatment and healing of wounds, as a cosmetic and in regenerative medicine. | 2022-09-22 |
| 20220298227 | TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS - This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and/or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and/or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal. | 2022-09-22 |
| 20220298228 | NOVEL EUKARYOTIC CELLS AND METHODS FOR RECOMBINANTLY EXPRESSING A PRODUCT OF INTEREST - The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the effect of the expression product of an endogenous gene C12orf35 is impaired in said cell, thereby increasing their productivity when recombinantly expressing a polypeptide of interest. Furthermore, the present disclosure provides associated technologies wherein such host cells are used in recombinant production technologies. | 2022-09-22 |
| 20220298229 | Antibodies to Andes Hantavirus, and Methods for Using Same - This invention provides isolated human antibodies and recombinant proteins comprising defined heavy chains and light chains, wherein the antibodies and recombinant proteins neutralize Andes Virus with defined IC50 values. This invention also provides related pharmaceutical compositions, treatment methods and kits. | 2022-09-22 |
| 20220298230 | ANTIBODIES AND METHODS FOR TREATMENT OF VIRAL INFECTIONS - The present invention provides antibodies that are capable of activating dendritic cell maturation and/or inducing a protective CDS response. The disclosed antibodies can be used to treat or inhibit viral infections, including prophylaxis and treatment of influenza A infection. The invention also provides nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies. | 2022-09-22 |
| 20220298231 | Novel Molecules for Therapy and Diagnosis - The present invention relates to novel molecules that can be employed for the prevention, alleviation, treatment and/or diagnosis of diseases, disorders and abnormalities associated with alpha-synuclein (a-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn, a-syn) aggregates, including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease, Multiple System Atrophy, Lewy Body dementia (LBD; dementia with Lewy bodies (DLB) (“pure” Lewy body dementia), Parkinson's disease dementia (FDD)) or Diffuse Lewy Body Disease. The invention relates to alpha-synuclein binding molecules, in particular to alpha-synuclein antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present molecules can also be used for determining a predisposition to such a disorder, disease or abnormality, monitoring residual disorder, disease or abnormality, or predicting the responsiveness of a patient who is suffering from such a disorder, disease or abnormality to treatment with a certain medicament. | 2022-09-22 |
| 20220298232 | METHODS FOR REDUCING DRUG-INDUCED LIVER INJURY - The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients. | 2022-09-22 |
| 20220298233 | Methods for Treatment of Subjects with Psoriatic Arthritis - This disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of psoriatic arthritis. | 2022-09-22 |
| 20220298234 | MACROPHAGE DIVERSITY IN REGENERATIVE, FIBROTIC BIOMATERIAL ENVIRONMENTS - The present invention provides methods for identification of distinct macrophage subsets which demonstrate previously unrecognized myeloid macrophage phenotypes involved in different tissue responses and provide new methods for therapeutic modulation of certain pathologic tissue states and tissue repair. | 2022-09-22 |
| 20220298235 | ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODY AND USE THEREOF - Provided is an antibody for the treatment or prevention of autoimmune diseases, comprising a heavy chain variable region represented by SEQ ID NO: 1 or SEQ ID NO: 24, and a light chain variable region represented by SEQ ID NO: 6, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 25. | 2022-09-22 |
| 20220298236 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody - A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16, 24, 52, and/or 100 weeks after initial treatment. | 2022-09-22 |
| 20220298237 | ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF - A subject of the present invention is to provide an anti AQP3 antibody specifically recognizing the extracellular domain of aquaporin 3 (AQP3), which is one type of a water channel protein. By selecting a monoclonal antibody which specifically binds to an oligopeptide included in loop C as the extracellular domains of AQP3, anti AQP3 antibodies that are desired in the present invention are provided. An anti AQP3 monoclonal antibody of the present invention can directly bind, from the outside of a cell, to AQP3 present in a cell membrane. Furthermore, as an anti AQP3 monoclonal antibody of the present invention can have an inhibitory activity, the function of permeating a low molecular weight molecule or the like, which is carried by AQP3, can be suppressed. | 2022-09-22 |
| 20220298239 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES - Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 2022-09-22 |
| 20220298240 | Bispecific Chimeric Antigen Receptor - The present invention relates to a bispecific chimeric antigen receptor, which can target both CD19 and CD22 proteins. T cells expressing the chimeric antigen receptor have good killing effect on tumor cells expressing CD19 and/or CD22 proteins. The chimeric antigen receptor of the present invention can realize a good killing effect on tumor cells with loss of CD19, and provides a more effective therapeutic way for tumor diseases. | 2022-09-22 |
| 20220298241 | USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES - The disclosure relates to methods for treating pemphigus and/or a pemphigoid disease in a subject in need thereof, wherein the methods include administering to a subject in need thereof a therapeutically effective amount of an FcRn inhibitor. In certain embodiments, the FcRn inhibitor is an anti-FcRn antibody or antigen-binding fragment thereof. | 2022-09-22 |
| 20220298242 | Bispecific Antibody Targeting CD3 and CD20 and Use Thereof - The present invention provides an anti-CD3 single chain Fab molecule and an anti-CD20 single chain Fab molecule and their use in preparation of a bispecific antibody. The present invention also provides a bispecific antibody targeting CD3 and CD20 and its use in preparation of a medicament for treatment of a B-cell related disease. | 2022-09-22 |
| 20220298243 | ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT - This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin. | 2022-09-22 |
| 20220298244 | ANTIBODIES BINDING PD-L1 AND USES THEREOF - An isolated monoclonal antibody, or an antigen-binding portion thereof, that specifically binds human PD-L1. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the antibody or antigen-binding portion thereof. | 2022-09-22 |
| 20220298245 | ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF - The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2022-09-22 |
| 20220298246 | ANTI-B7-H3 ANTIBODY AND METHODS OF USE THEREOF - The present disclosure provides antibodies that specifically bind to B7-H3. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. The present disclosure provides antibodies that specifically bind to B7-H3. A subject antibody specifically binds B7-H3 from humans and other mammals, e.g., monkey and mouse. | 2022-09-22 |
| 20220298247 | COMBINATION THERAPY WITH A MEK INHIBITOR, A PD-1 AXIS INHIBITOR, AND A VEGF INHIBITOR - A combination therapy comprising a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor is provided for the treatment of colorectal cancer and metastatic colorectal cancer. | 2022-09-22 |
| 20220298248 | Treatment of Cancers Lacking EGFR- Activating Mutations - The present invention relates to treatment of subjects having cancers with tumors lacking an at least one EGFR-activating mutation. | 2022-09-22 |
| 20220298249 | METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS - The present disclosure relates to the use of competitive inhibitors of the CCR5 receptor, such as the monoclonal antibody leronlimab, or binding fragments thereof, in the treatment or prevention of cancer. | 2022-09-22 |
| 20220298250 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR - The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. | 2022-09-22 |
| 20220298251 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES - The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas. | 2022-09-22 |
| 20220298252 | METHODS OF TREATING CANCER USING TNFRSF25 ANTIBODIES - The present disclosure is directed to a method of treating cancer using a TNFRSF25 agonistic antibody or antigen binding fragment thereof and their combinations with additional therapies such as cancer vaccines and/or checkpoint inhibitors. | 2022-09-22 |
| 20220298253 | TREATMENT OF RMS BY SWITCHING THERAPY - The present invention relates to the anti-CD20 monoclonal antibody ofatumumab for use in the treatment or prevention of relapsing multiple sclerosis, wherein ofatumumab is used in a patient who has been treated with a disease-modifying therapy other than ofatumumab. | 2022-09-22 |
| 20220298254 | CD47 ANTIGEN-BINDING MOLECULES - CD47 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the CD47 antigen-binding molecules. | 2022-09-22 |
| 20220298255 | E-CADHERIN ACTIVATING ANTIBODIES AND USES THEREOF - Provided herein are several monoclonal antibodies that activate the adhesion activity of human and mouse E-cadherin, including the amino acid sequences for the CDRs that define the binding domains of each monoclonal antibody. Also described are methods of making these antibodies, as well as biologically functional fragments and derivatives thereof; and methods of using them in the treatment, prevention, and/or amelioration of disease and conditions characterized by disruption of normal cell adhesion and/or cell junctions. Specifically contemplated are methods and compositions for the treatment of cancer metastasis as well as inflammatory conditions (such as inflammatory bowel disease and airway inflammation). | 2022-09-22 |
| 20220298256 | MODIFIED FC-REGIONS TO ENHANCE FUNCTIONAL AFFINITY OF ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF - The present invention relates to the identification of key residues within mouse lgG3 antibodies (mAbs) that are responsible for intermolecular cooperativity and their transfer into lgG1 antibodies in order to enhance their functional affinity and direct cell killing. | 2022-09-22 |
| 20220298257 | ANTI-CD22 ANTIBODIES AND USES THEREOF - Disclosed herein are high affinity anti-CD22 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-CD22 antibodies. | 2022-09-22 |
| 20220298258 | PSGL-1 Antagonists and Uses Thereof - Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides. | 2022-09-22 |
| 20220298259 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER - The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system. | 2022-09-22 |
| 20220298260 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF - Provided herein are antigen-binding protein constructs capable of specifically binding FOLR1 or an epitope of FOLR1 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs. | 2022-09-22 |
| 20220298261 | Serpinf2-Binding Molecules and Method of Use Thereof - Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided. | 2022-09-22 |
| 20220298262 | Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury - Methods and pharmaceutical compositions for treating ischemic injury are provided. The methods include administering a therapeutically effective amount of a vascular matrix metalloproteinase 9 (MMP-9) inhibitor that reduces ischemic injury in a subject. | 2022-09-22 |
| 20220298263 | METHODS AND FORMULATIONS FOR REDUCING RECONSTITUTION TIME OF LYOPHILIZED POLYPEPTIDES - The present invention relates to methods and formulations useful for reducing the reconstitution time of lyophilized polypeptides. | 2022-09-22 |
| 20220298264 | A MOULDABLE FIBROUS SHEET AND A PRODUCTION METHOD THEREOF - The present invention relates to a web of fibrous cellulosic material derived from wood pulp, said web being suitable for three-dimensional moulding to form a packaging product, wherein the web comprises >40 wt % of soft wood chemical pulp and at least one strength enhancement agent, wherein the web has a grammage less than 400 g/m | 2022-09-22 |
| 20220298265 | AMPHIPHILIC POLYSACCHARIDES, POLYSACCHARIDE-BASED HYDROGELS, AND METHODS OF MANUFACTURE - A method for the synthesis of alkyl ω-carboxy(hydroxyethyl) polysaccharides is described. The method includes methylating or ethylating a polysaccharide or providing a methylated or ethylated polysaccharide, hydroxyethylating the methylated or ethylated polysaccharide, and oxidizing the hydroxyethylated polysaccharide to form the ω-carboxy(hydroxyethyl) polysaccharide. A method for the synthesis of oxidized polysaccharides is also described. The method includes hydroxypropylating a polysaccharide and oxidizing the hydroxypropylated polysaccharides. A method for the production of a solid capable of forming a hydrogel is also described. The method includes combining a first solution comprising an oxidized oligo(hydroxypropyl) polysaccharide bearing one or more ketone groups with a second solution comprising an amine substituted polysaccharide to form a third solution, and removing solvent from the third solution to form the solid, or adding an additional solvent to the third solution to precipitate the solid. Novel polysaccharides and hydrogels prepared according to these methods are also described. | 2022-09-22 |
| 20220298266 | CENTRIC SPRAY PIPE - A centric spray pipe apparatus is disclosed, The centric spray pipe includes a plurality of nozzles designed to provide full coverage of liquid spray to a vessel. | 2022-09-22 |
| 20220298267 | CURED RESIN FORMATION METHOD AND CURED RESIN FORMATION DEVICE - A cured resin formation method including an applying step of applying an ultraviolet curable resin on a base; and a curing step of curing the ultraviolet curable resin by irradiating the ultraviolet curable resin applied in the applying step with ultraviolet rays, in which in the curing step, the ultraviolet curable resin is irradiated with ultraviolet rays while cooling the ultraviolet curable resin, so that a difference between an ordinary temperature of the ultraviolet curable resin and a temperature of the ultraviolet curable resin when irradiated with ultraviolet rays is within a set temperature difference set in advance. | 2022-09-22 |
| 20220298268 | Photobase Generator, Compound, Photoreactive Composition, and Reaction Product - A photobase generator includes a compound including a first skeleton represented by the following formula (a), and a second skeleton including a nitrogen atom bonding to a bonding position of the first skeleton to form an amide group, wherein the compound generates a base, in which a hydrogen atom is bonding with the nitrogen atom of the second skeleton, by light irradiation, and the pKa of a conjugate acid of the base in water is 12 or more. In formula (a), G is a divalent aromatic group, and * represents the bonding position with the nitrogen atom. | 2022-09-22 |
| 20220298269 | Active Energy Ray Curable Composition - Provided is an active energy ray curable composition cured by irradiation of active energy rays. The active energy ray curable composition contains an (A) radical polymerizable compound, a (B) photopolymerization initiator, and a (C) amine compound. The (B) photopolymerization initiator includes a (B1) sulfur compound and a (B2) acyl phosphine oxide compound. The (B1) sulfur compound is at least one of a sulfone compound and a thiobenzoyl compound. | 2022-09-22 |
| 20220298270 | PHOTOCURABLE COMPOSITIONS FOR STEREOLITHOGRAPHY, METHOD OF FORMING THE COMPOSITIONS, STEREOLITHOGRAPHY METHODS USING THE COMPOSITIONS, POLYMER COMPONENTS FORMED BY THE STEREOLITHOGRAPHY METHODS, AND A DEVICE INCLUDING THE POLYMER COMPONENTS - A photocurable composition for stereolithographic three-dimensional printing, wherein the photocurable composition comprises a photoreactive oligomer component comprising a hydrophobic oligomer comprising a photoreactive end group, a photoreactive monomer component comprising a photoreactive monomer having a photoreactive end group, and a photoinitiation composition comprising a photoinitiator; the photocurable composition has a viscosity of 250 to 10,000 centipoise at 22° C., determined using a Brookfield viscometer; and the photocured composition has a dielectric loss of less than 0.010, preferably less than 0.008, more preferably less than 0.006, most preferably less than 0.004, each determined by split-post dielectric resonator testing at 10 gigahertz at 23° C. | 2022-09-22 |
| 20220298271 | A PROCESS FOR PREPARATION OF A CATALYST WITH A POLYOLEFIN COAT - The present disclosure relates to a process for preparation of a catalyst with a polyolefin coat. The process of the present disclosure is simple, economical and requires 50% less reaction time to obtain a desired catalyst with polyolefin coat. The catalyst obtained by the process of the present disclosure is capable of reducing generation of polymer fines by at least 50%, which leads to improved plant operability and throughput. | 2022-09-22 |
| 20220298272 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS - A solid catalyst component for the polymerization of olefins made from or containing a magnesium halide, a titanium compound having at least a Ti-halogen bond, a first electron donor compound selected from 1,3 diethers (DE), and a second electron donor compound selected from dicarbamates (DC), wherein the first and second electron donor compounds are present in a molar ratio DE:DC ranging from 4.5:1 to 20:1. | 2022-09-22 |
| 20220298273 | Process to Produce Low Viscosity Polyalphaolefins using Non-Aromatic-Hydrocarbon Soluble Activators - A process for making a poly alpha-olefin (PAO) having high vinylidene content (or combined vinylidene and tri-substituted vinylene content) and low vinyl and/or di-substituted vinylene content, as well as a relatively low molecular weight comprising contacting a feed containing a C | 2022-09-22 |
| 20220298274 | IMPROVED SOLUTION-PROCESSABLE TRIAZOLE-BASED POLYMERS AND METHODS OF MAKING THE SAME - Disclosed herein are polymers comprising at least one alkyne functional group, at least one azide functional group, and a conformational bend outside of coplanarity of 30 or greater. Also disclosed herein are methods of making and using the same. | 2022-09-22 |
| 20220298275 | SULFUR-CONTAINING UNSATURATED HYDROCARBON POLYMER AND METHOD FOR PRODUCTION THEREOF, ADDITIVE FOR RUBBER, RUBBER COMPOSITION, AND TIRE - Provided is a sulfur-containing unsaturated hydrocarbon polymer which can improve wet grip performance and fuel efficiency of a tire in a well-balanced manner by being blended into a rubber composition for a tire. A sulfur-containing unsaturated hydrocarbon polymer of the present invention is a reaction product obtained by reacting sulfur with an unsaturated bond in a polymer of an unsaturated hydrocarbon. | 2022-09-22 |
| 20220298276 | CROSSLINKED PTFE - The present application relates generally to tubes, such as thin walled catheter liners with small wall thicknesses (e.g., less than 1 mm), including crosslinked fluoropolymers, e.g., crosslinked poly(tetrafluoroethylene). The disclosure further provides methods of manufacturing such tubes and systems for manufacturing such tubes. | 2022-09-22 |
| 20220298277 | POLYMER EMULSION AND MANUFACTURING METHOD THEREOF - A method for manufacturing a polymer emulsion includes the following steps. A mixture is heated to a first temperature less than or equal to about 40° C. The mixture including about 100 to about 500 parts by weight of a monomer and about 0.5 to about 95 parts by weight of a first cross-linking agent, in which the monomer has a structure of formula (I): | 2022-09-22 |
| 20220298278 | METHOD FOR CONTROLLING MOONEY VISCOSITY OF PEROXIDE-CURED FLUORORUBBER - The present invention provides a method for controlling Mooney viscosity of peroxide-cured fluororubber. The method comprises: adding an initiator solution in a continuous supplementary manner during the emulsion polymerization process of a peroxide-cured fluororubber until 5 to 10 minutes before the end of the polymerization reaction; wherein the amount of the initiator solution added initially is 0.1% to 0.5% of the total amount of the polymerization monomer dry materials, and the amount of the initiator solution continuously supplemented is 0.1% to 2% of the total amount of the polymerization monomer dry materials, based on the initiator. The present invention effectively controls the Mooney viscosity value of the peroxide-cured fluororubber within the desired range with small fluctuations by controlling the amount and the manner of addition of the initiator, thereby obtaining a peroxide-cured fluororubber with stable and controllable quality. Moreover, the present invention does not need to add a chain transfer agent, which reduces the amount of additives in the polymerization process, and meanwhile improves the reaction activity of the polymerization system, effectively shortens the time for polymerization, and is beneficial to industrialized production. | 2022-09-22 |
| 20220298279 | RESIN COMPOSITION AND DISPLAY DEVICE USING THE SAME - A resin composition of an embodiment includes a (meth)acrylate monomer, a photoinitiator, and a moisture absorbent, wherein the moisture absorbent includes a hydrolysable group, and a carboxyl group after hydrolysis, thereby providing a display device with improved tolerance to moisture and moisture permeability. | 2022-09-22 |
| 20220298280 | ANTIBACTERIAL POLYMER PARTICLES, COMPOSITION, AND ARTICLE - One aspect of the present invention includes, in antibacterial polymer particles, a crosslinked copolymer having a structural unit derived from a monofunctional monomer having an antibacterial group, and a structural unit derived from a polyfunctional monomer. A water absorption capacity of the antibacterial polymer particles is 3 g/g or more. | 2022-09-22 |
| 20220298281 | Bismaleimide Compound, Composition Containing Same, Polybenzoxazole, And Semiconductor Device - An object of the present invention is to provide a novel photosensitive resin precursor that can be developed with an alkali and ring-closed even at low temperatures, and preferably has excellent thermal properties and excellent electric properties after curing, and also to provide a use application thereof. As means for achieving the object, disclosed are a bismaleimide compound comprising, in one molecule, two partial structures in each of which a carbon atom having a substituent represented by the following formula (A) (wherein Y represents a direct bond or a divalent linking group), and a carbon atom having a hydroxy group are directly bonded to each other, a polymer which is a self-polymer of the bismaleimide compound, and a benzoxazole which is an intramolecular dehydrated ring-closed product of the polymer. | 2022-09-22 |
| 20220298282 | PHOTO-INDUCED CATIONIC POLYMERIZED PURE VEGETABLE OIL-BASED POLYMER, PREPARATION METHOD AND USE THEREOF - The present invention relates to a photo-induced cationic polymerized pure vegetable oil-based polymer and a preparation method and use thereof. The preparation method comprises the following steps: mixing a dry oil, an epoxy vegetable oil and an initiator uniformly, irradiating to initiate a photo-curing reaction, and then placing at ambient temperature, and continuing to a heat-curing reaction so as to obtain a photo-induced cationic polymerized pure vegetable oil-based polymer. In the present invention, vegetable oil resources which are low in price, widespread, and easy to regenerate are used to prepare the pure vegetable oil-based polymers instead of the fossil-derived monomers completely, thereby achieving the efficient use of vegetable oils. In the present invention, an unconventional photo-induced heat frontal polymerization technology is used to prepare the pure vegetable oil-based polymer, thereby achieving a photo-thermal dual curing reaction of a vegetable oil system without heating. The preparation method of the present invention is simple, mild in the conditions, energy-saving and environment-friendly, stable in the product quality, and suitable for large-scale production. | 2022-09-22 |
| 20220298283 | ONE COMPONENT (1K) COMPOSITION BASED ON EPOXY RESIN - The present invention is directed to an one-component (1K) composition comprising, based on the weight of the composition:
| 2022-09-22 |
| 20220298284 | CORE-SATELLITE MICELLE INCLUDING TETRA-BLOCK COPOLYMER AND PREPARATION METHOD THEREOF - Proposed are a core-satellite micelle containing a tetra-block copolymer and a preparation method thereof. The core-satellite micelle includes a core, a shell surrounding the core, and a plurality of satellite domains positioned inside the shell. The core-satellite micelle contains a tetra-block copolymer represented by Structural Formula 1 below. The shell includes a first-monomer first block A1 and a first-monomer second block A2, and the satellite domain includes a second-monomer first block B1 and a second-monomer second block B2. The core-satellite micelle is foiled through self-assembly of the tetra-block copolymer, thereby having a larger interfacial contact area than existing block-copolymer micelles. Therefore, the core-satellite micelle can be used in next-generation nanotechnology applications such as drug delivery systems, porous catalyst materials, and sensors. | 2022-09-22 |
| 20220298285 | LIPOPHYLIC COPOLYMERS COMPRISING POLAR MULTI-BLOCKS, PROCESS FOR THE PREPARATION THEREOF AND USE IN LUBRICATING COMPOSITIONS - A lipophilic copolymer including polar multi-blocks having general formula (I): | 2022-09-22 |
| 20220298286 | POLYURETHANE-POLYISOCYANURATE COMPOUND WITH OUTSTANDING MECHANICAL PROPERTIES - Described herein is a process for preparing a polyurethane-polyisocyanurate compound by mixing a) at least one polyisocyanate; b) a mixture (M); c) at least one compound including one or more epoxide groups; d) at least one aliphatic polyol (P1) having a high weight average molecular weight; e) at least one polyol (P2) having a low weight average molecular weight; f) at least one compatibilizer; and, optionally, g) fillers and further additives to form a reaction mixture (RM); and reacting the mixture (RM) to give the polyurethane-polyisocyanurate compound. Also described herein are a polyurethane-polyisocyanurate compound obtainable by the process and a method of using the polyurethane-polyisocyanurate compound for producing bodywork components for vehicles. | 2022-09-22 |
| 20220298287 | BIOMEDICAL DEVICES - A biomedical device is disclosed which is a polymerization product of a mixture comprising (a) one or more difunctional isocyanates; (b) one or more polyalcohols; (c) one or more hydroxy-terminated polysiloxane prepolymers; and (d) one or more polyoxazoline polyols having a weight average molecular weight of equal to or greater than about 1000 Daltons. | 2022-09-22 |
| 20220298288 | CATALYSTS FOR POLYURETHANE FOAM POLYOL PREMIXES CONTAINING HALOGENATED OLEFIN BLOWING AGENTS - The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to closed-celled, polyurethane and polyisocyanurate foams and methods for their preparation. The foams are characterized by a fine uniform cell structure and little or no foam collapse. The foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol, a silicone surfactant, and a non-amine catalyst used alone or in combination with an amine catalyst. | 2022-09-22 |
| 20220298289 | TWO-COMPONENT POLYURETHANE COMPOSITION - A two-component polyurethane composition comprising (A) an aqueous dispersion comprising an emulsion polymer and from 2% to 20% of an alcohol alkoxylate of formula (I), by weight based on the weight of the emulsion polymer, and (B) a polyisocyanate; the two-component polyurethane composition can provide coatings with a high distinctness of image. | 2022-09-22 |
| 20220298290 | URETHANE RESIN COMPOSITION AND MOISTURE-PERMEABLE FILM - An object of the invention is to provide a urethane resin composition containing a biomass raw material and having excellent moisture permeability and excellent film strength. The invention provides a urethane resin composition containing a urethane resin (X), the urethane resin (X) containing, as essential raw materials, a polyol (A) that contains a polyol (a1) having an oxyethylene group, and a polyisocyanate (B), in which the polyol (A) further contains a polyester polyol (a2) containing a biomass-derived glycol (i) and a crystalline polybasic acid (ii) as raw materials, and the polyol (A) has a hydroxyl equivalent in a range of 400 g/eq to 600 g/eq. In addition, the invention provides a moisture-permeable film which is formed of the urethane resin composition. | 2022-09-22 |
| 20220298291 | NON-MIXED AMPHIPHILIC THERMOPLASTIC POLYURETHANE, METHOD FOR PRODUCING SAME, AND IMPLANTABLE MEDICAL DEVICE INCLUDING SAME - The present invention relates to an amphiphilic polymer copolymer composed of a prepolymer polymerized by reacting polyol (P) and diisocyanate (R) and a chain-extender comprising one or more hydrophilic or hydrophobic functional groups (E | 2022-09-22 |
| 20220298292 | POLYURETHANE FOAM - A composition for producing a flame retardant open-celled semi-rigid polyurethane foam including: (a) at least one polyisocyanate, (b) at least one polyol, (c) at least one expandable graphite, (d) at least one blowing agent, (e) at least one catalyst, (f) at least one liquid flame retardant, (g) at least one cell opener, (h) at least one ethoxylated alcohol, and (i) at least one antioxidant; a process for producing the above composition; a flame retardant open-celled semi-rigid polyurethane foam produced using the above composition; and a process for producing the above flame-retardant open-celled semi-rigid polyurethane foam. | 2022-09-22 |
